Opendata, web and dolomites

ONCOGENEVOL SIGNED

The evolutionary history of oncogenic and non-oncogenic papillomaviruses

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ONCOGENEVOL project word cloud

Explore the words cloud of the ONCOGENEVOL project. It provides you a very rough idea of what is the project "ONCOGENEVOL" about.

wart    host    dna    viruses    became    regarding    responsible    asymptomatic    occurred    emergence    function    genome    proteins    proto    suppressor    oncogenes    efforts    events    hypotheses    integration    generate    explore    contexts    virtually    oncogenic    cancer    vagina    understand    wet    ancestral    experimentally    exception    resurrected    anal    combining    sharing    immune    pv    vulva    paving    evolutionary    thereafter    health    enigma    oropharynx    infection    few    directed    alphapv    phenotype    species    genes    share    oncogene    clinical    penis    cancers    ultimate    roots    tracking    modern    history    scenario    benign    certain    acquired    carcinogenesis    evolution    allowed    public    appearance    humans    pvs    deep    tumor    hosts    despite    fraction    infections    encode    evade    acquiring    fragmentary    environmental    cervical    ancestor    medicine    back    actually    arose    human    silico    lesions    lab    functions    resurrect    e7    e5    manifestations    relationships    origin    small    papillomaviruses    unfortunate    e6    domains   

Project "ONCOGENEVOL" data sheet

The following table provides information about the project.

Coordinator
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS 

Organization address
address: RUE MICHEL ANGE 3
city: PARIS
postcode: 75794
website: www.cnrs.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://virostyle.cnrs.fr/projects/oncogenevol/
 Total cost 185˙076 €
 EC max contribution 185˙076 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-06-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) coordinator 185˙076.00

Map

 Project objective

Certain papillomaviruses (PVs) are a major public health concern as in humans they are responsible for virtually all cases of cervical and anal cancer, and for a fraction of cancers on the penis, vagina, vulva and oropharynx. But oncogenic PVs are actually an unfortunate exception, as most PVs cause asymptomatic infections, and a few cause benign, wart-like lesions. Despite the efforts directed towards the understanding of the different clinical manifestations of infection, our knowledge on PV evolution remains fragmentary. Oncogenic human PVs arose recently, after acquiring the E5, E6 and E7 genes. The integration of the E5 proto-oncogene in the ancestral AlphaPV genome allowed viruses to evade host immune response. Thereafter E6 and E7 acquired the ability to target essential tumor suppressor proteins, paving the way for carcinogenesis. Tracking the evolutionary history of the E5, E6 and E7 oncogenes will thus help understand the emergence of oncogenic human PVs. Regarding the deep roots of PVs, small DNA viruses may share a common ancestor as they encode proteins sharing similar functions and domains, but their evolutionary origin is still an enigma. Here I propose to apply an evolutionary medicine approach, combining in silico and wet-lab approaches, to study key events that occurred during PV genome evolution. We will go back into history and study how and when certain PVs became oncogenic. We will resurrect the ancestral oncogenes, and experimentally test hypotheses about the function of the resurrected proteins in different environmental contexts. We will then generate a comprehensive scenario modelling the appearance of the modern PV genome and the emergence of the oncogenic phenotype of certain PVs. Finally we will explore the relationships between small DNA viruses and test whether they may have a common origin. Our ultimate aim is to understand why a few PVs are oncogenic for a few host species, while most PVs cause asymptomatic infections in most hosts.

 Publications

year authors and title journal last update
List of publications.
2019 Anouk Willemsen, Marta Félez-Sánchez, Ignacio G Bravo
Genome Plasticity in Papillomaviruses and De Novo Emergence of E5 Oncogenes
published pages: 1602-1617, ISSN: 1759-6653, DOI: 10.1093/gbe/evz095
Genome Biology and Evolution 11/6 2019-09-02
2019 Anouk Willemsen, Ignacio G. Bravo
Origin and evolution of papillomavirus (onco)genes and genomes
published pages: 20180303, ISSN: 0962-8436, DOI: 10.1098/rstb.2018.0303
Philosophical Transactions of the Royal Society B: Biological Sciences 374/1773 2019-06-06

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOGENEVOL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCOGENEVOL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

LiverMacRegenCircuit (2020)

Elucidating the role of macrophages in liver regeneration and tissue unit formation

Read More  

CYBERSECURITY (2018)

Cyber Security Behaviours

Read More  

ROSETTA (2020)

Deciphering the Role of aberrant glycOSylation in the rEsponse to Targeted TherApies for breast cancer

Read More